Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. AbbVie Inc.
  6. News
  7. Summary
    ABBV   US00287Y1091

ABBVIE INC.

(ABBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AbbVie : Files Regulatory Applications in US and Europe for Upadacitinib to Treat Adults With Ulcerative Colitis

09/16/2021 | 09:44am EDT


© MT Newswires 2021
All news about ABBVIE INC.
10/15REVANCE THERAPEUTICS : U.S. FDA declines to approve Revance's frown-line treatment
RE
10/15ABBVIE : Says its Psoriatic Arthritis Drug Risankizumab Recommended by CHMP for Treatment ..
MT
10/15AbbVie Gets CHMP Positive Opinion for Risankizumab in Psoriatic Arthritis
DJ
10/14PRESS RELEASE : Roche's Gazyvaro shorter 90-minute infusion time approved in Europe for pe..
DJ
10/14ABBVIE INC. : Ex-dividend day for
FA
10/12ABBVIE : Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer Aware..
AQ
10/11Health Care Stocks Sliding in Late Monday Trading
MT
10/11Health Care Stocks Drifting Monday as Biotechs Climb
MT
10/08ABBVIE : Upadacitinib (RINVOQ) Met Primary and Most Ranked Secondary Endpoints in Phase 3 ..
AQ
10/08ABBVIE : RINVOQ (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 S..
AQ
More news
Analyst Recommendations on ABBVIE INC.
More recommendations
Financials (USD)
Sales 2021 56 204 M - -
Net income 2021 12 473 M - -
Net Debt 2021 66 426 M - -
P/E ratio 2021 14,9x
Yield 2021 4,68%
Capitalization 193 B 193 B -
EV / Sales 2021 4,62x
EV / Sales 2022 4,14x
Nbr of Employees 48 000
Free-Float 98,0%
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | ABBV | US00287Y1091 | MarketScreener
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 109,33 $
Average target price 125,48 $
Spread / Average Target 14,8%
EPS Revisions
Managers and Directors
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman-Management Board & President
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Azita Saleki-Gerhardt Executive Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ABBVIE INC.2.03%193 205
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.12.71%232 621
ELI LILLY AND COMPANY40.89%215 657